打开APP

卫材酪氨酸激酶抑制剂Lenvatinib III期甲状腺癌研究显著改善无进展生存期

  1. lenvatinib
  2. 分化型甲状腺癌
  3. 卫材
  4. 酪氨酸激酶抑制剂

来源:生物谷 2014-06-04 09:00

卫材多激酶抑制剂lenvatinib III期SELECT研究,显著改善分化型甲状腺癌患者疾病无进展生存期(PFS)。

2014年6月4日讯 /生物谷BIOON/ --卫材(Eisai)近日公布了实验性抗癌药物lenvatinib(E7080)III期SELECT研究的数据。该研究是一项多中心、随机、双盲、安慰剂对照III期研究,调查了口服lenvatinib(24mg)治疗放射性碘131抵抗的分化型甲状腺癌(RR-DTC)的疗效,主要终点为无进展生存期(PFS),次要终点包括总缓解率(ORR),总生存期(OS)和安全性。

数据表明,与安慰剂组相比,lenvatinib治疗组无进展生存期(PFS)显著延长(18.3个月 vs 3.6个月,p<0.0001),达到了研究的主要终点。目前,该研究的总生存期(OS)数据尚未获得。相关数据已提交至美国临床肿瘤学会(ASCO)第50届年会。

Lenvatinib是一种口服多受体酪氨酸激酶(RTK)抑制剂,具有新颖的结合模式,除抑制参与肿瘤增殖的其他促血管生成和致癌信号通路相关RTK外,还能够选择性抑制血管内皮生长因子(VEGF)受体的激酶活性。(生物谷Bioon.com)

英文原文:LENVATINIB PHASE III RESULTS SHOW SIGNIFICANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL IN PATIENTS WITH RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER

Phase III data for lenvatinib to be presented in a Head and Neck Cancer oral session at ASCO
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, “Eisai”) announced today the results from the Phase III SELECT trial of lenvatinib (E7080), a novel investigative anti-cancer agent for patients with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC). Progression-free survival (PFS) with lenvatinib was extended significantly compared to placebo (Hazard Ratio (HR) 0.21; 99% CI: 0.14-0.31; p<0.0001). The median PFS with lenvatinib and placebo were 18.3 months and 3.6 months respectively. These data will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in a Head and Neck Cancer oral session on Monday, June 2, and as part of the official press program on Saturday, May 31 (Abstract No. LBA6008).

Lenvatinib is an oral multiple receptor tyrosine kinase (RTK) inhibitor with a novel binding mode that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors, in addition to other proangiogenic and oncogenic pathway-related RTKs involved in tumor proliferation. The SELECT (Study of E7080 “LEnvatinib” in Differentiated Cancer of the Thyroid) study confirmed a statistically significant benefit for treatment with lenvatinib on PFS in all predefined subgroups. Secondary endpoints included overall response rate (ORR*), overall survival (OS) and safety. Rates of complete response were 1.5% (4 patients) for the lenvatinib group and zero in the placebo group. The results for partial response were 63.2% (165 patients) in the lenvatinib group and 1.5% (2 patients) in the placebo group. The median exposure duration was 13.8 months for lenvatinib and 3.9 months for placebo, and the median time to response for lenvatinib was 2.0 months. Median OS has not been reached yet.
*Overall Response Ratio (ORR): Sum of Complete Response and Partial Response

The five most common lenvatinib treatment-related adverse events (TRAEs) of any grade were hypertension (67.8%), diarrhea (59.4%), decreased appetite (50.2%), weight loss (46.4%) and nausea (41.0%). TRAEs of Grade 3 or higher (Common Terminology Criteria for Adverse Events) included hypertension (41.8%), proteinuria (10.0%), weight loss (9.6%), diarrhea (8.0%), and decreased appetite (5.4%).

Differentiated thyroid cancer is the most common form of thyroid cancer and accounts for approximately 95% of all thyroid cancers. Among these differentiated thyroid cancers, some are radioiodine-refractory (RR-DTC) and cannot easily be cured with surgery and radioactive iodine treatment, which presents a significant unmet medical need as treatment options are limited for RR-DTC.

“These positive Phase III results show the benefit of lenvatinib for this aggressive form of thyroid cancer where for which there are currently limited options for treatment,” commented Professor Martin Schlumberger, Primary Investigator and M.D. Institut Gustave Roussy, University Paris Sud, Paris, France.

Eisai will submit regulatory applications for lenvatinib to health authorities in Japan, the United States (U.S.) and Europe. Lenvatinib was granted Orphan Drug Designation for thyroid cancer in Japan, Europe and the U.S. Eisai has also initiated a global Phase III trial of lenvatinib in hepatocellular carcinoma and is conducting Phase II studies of lenvatinib in several other tumor types. Eisai is committed to exploring the potential clinical benefits of lenvatinib in order to further contribute to patients with cancer, including patients with thyroid cancer, and their families.

[ Please refer to the following notes on lenvatinib, the SELECT study and thyroid cancer. ]

< Notes to editors >

1. About Lenvatinib (E7080)
   Lenvatinib, discovered and developed by Eisai, is an oral multiple receptor tyrosine kinase (RTK) inhibitor with a novel binding mode that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors (VEGFR1 (FLT1), VEGFR2 (KDR) and VEGFR3 (FLT4)), in addition to other proangiogenic and oncogenic pathway-related RTKs (including fibroblast growth factor (FGF) receptors FGFR1, 2, 3 and 4; the platelet-derived growth factor (PDGF) receptor PDGFRα; KIT; and RET) involved in tumor proliferation. It is currently under development as a potential treatment for thyroid cancer, hepatocellular carcinoma (Phase III), non-small cell lung cancer (Phase II) and other solid tumor types. Lenvatinib was granted Orphan Drug Designation in Japan for thyroid cancer in August 2012, in the United States for treatment of follicular, medullary, anaplastic, and metastatic or locally advanced papillary thyroid cancer in December 2012 and in Europe for follicular and papillary thyroid cancer in April 2013.

2. About the SELECT study
   The SELECT (Study of (E7080) LEnvatinib in Differentiated Cancer of the Thyroid) study was a multicenter, randomized, double-blind, placebo-controlled Phase III study to compare the PFS of patients with RR-DTC and radiographic evidence of disease progression within the prior 13 months, treated with once-daily, oral lenvatinib (24mg) versus placebo. The study enrolled 392 patients in over 100 sites in Europe, North and South America and Asia and was conducted by Eisai in collaboration with the SFJ Pharmaceuticals Group.
   Participants were stratified by age (≤65, >65 years), region and ≤1 prior VEGFR-targeted therapies and randomized 2:1 to either lenvatinib or placebo therapy (24mg/d, 28-d cycle). The primary endpoint was PFS assessed by independent radiologic review. The secondary endpoints of the study included overall response rate (ORR), overall survival (OS) and safety.

3. About Thyroid Cancer
   Thyroid cancer refers to cancer that forms in the tissues of the thyroid gland, located at the base of the throat near the trachea. It is more common in women than in men and usually occurs between the ages of 25 and 65. The most common types of thyroid cancer, papillary and follicular (including Hürthle cell), are classified as differentiated thyroid cancer and account for approximately 95% of all cases. The remaining cases are classified as either undifferentiated (3-5% of cases) or medullary carcinoma (1-2% of cases). While most differentiated thyroid cancer patients are curable with surgery and radioactive iodine treatment, a small percentage of patients do not respond to therapy. There are limited treatment options for this difficult-to-treat, life-threatening and treatment-refractory form of thyroid cancer.

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->